Status:
COMPLETED
Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets
Lead Sponsor:
Zeria Pharmaceutical
Conditions:
Primary Hypophosphatemic Rickets
Eligibility:
All Genders
1-14 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the efficacy and safety of oral phosphate (Z-521) in subjects with primary hypophosphatemic rickets.
Eligibility Criteria
Inclusion
- Diagnosed as primary hypophosphatemic rickets based on familial history, genetic test or laboratory test results.
Exclusion
- A hyperparathyroidism
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01237288
Start Date
September 1 2010
End Date
July 1 2013
Last Update
October 1 2013
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Chiba Children's Hospital
Chiba, Japan
2
Kanagawa Children's Medical Center
Kanagawa, Japan
3
Osaka University Hospital
Osaka, Japan
4
Tokyo Metropolitan Children's Medical Center
Tokyo, Japan